Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Chemoradiation for Early Stage Esophageal Adenocarcinoma
NCT05713838Phase 2Active, not recruiting
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Aug 2023
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in esophageal adenocarcinoma (EAC), sponsored by Institut für Klinische Krebsforschung. Started Aug 2023; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT05713838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05713838.